Dr. Wang received his PhD in Physical Pharmacy from University of Utah under Dr. William Higuchi. As the CSO he is responsible for the overall science and technical management of the company. Prior to this position, Dr. Wang was the Director of Formulation Development, at Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT. In this role, he provided strategic leadership to a team focused on formulation and process development of NCE products. Dr. Wang is specialized in formulation development of poorly water soluble compounds for oral delivery and experienced in the development of oral solid dosage forms (tablets, hard gelatin capsules, soft gelatin capsules), oral liquid dosage forms (solutions and suspensions), controlled release technology, and parenterals (lyophilization). Under his leadership, his team introduced and implemented multiple new formulation technologies including SEDDS (self emulsifying drug delivery system) formulation technologies (soft gel and hard gel encapsulation capabilities), solid dispersion formulation technologies (spray drying and melt extrusion) as well as nano-milling. He has 30 peer-reviewed publications and patents, as well as numerous poster presentations.

Dr. Deepak Hegde completed his Doctorate in Biopharmaceutics and Pharmacokinetics from University of Mumbai in 1996, and his Masters in Financial Management (M.F.M) from University of Mumbai in 2000.

Prior to Pharmacin, Dr Hegde worked with EOC Pharma as Chief Technology Officer where he was responsible for development and manufacturing of new anti-cancer products for China. Dr Hedge also has served as Director, Global External Development & Supply, AsiaPacific at GSK Shanghai, R & D China where he was responsible for developing drug products for the global portfolio and for introduction of new products to China. Dr Hegde has also held roles at WuXi Apptec as Vice President for Formulation Development, Rhone Poulenc, Sandoz (A Novartis Group Company) and USV Ltd, a premier Indian Generic Company. He is a life member of the Indian Pharmaceutical Association, and has two US patents, five PCT and US patent applications and several National and International publications to his credit.

Dr. Wang is Vice President of Translational Sciences, responsible for evaluation and managing our pipelines to make highly differentiated and globally competitive medicines.

Prior to joining Pharmacin, Dr. Wang participated in creation of Vivoz Biolabs and served as the CEO of the company. She also worked in R&D centers of Boehringer Ingelheim in the US and Abbott (currently AbbVie) in China to lead/co-lead multi-disciplinary teams on multiple projects. In addition, she was responsible for new target proposals, new target evaluations for in-licensing and external collaborations. Dr. Wang has extensive experience in early drug discovery processes, from target validation, assay development, high-throughput screen, activity evaluation, to lead optimization, etc.

Dr. Wang earned a bachelor’s degree in biochemistry from Beijing University and a doctorate in molecular from University of Pennsylvania, and completed her postdoctoral fellowship training at Harvard University Medical School.

Dr. Wang authored or co-authored in numerous scientific publications in many prestige journals, including Cell.

Mr. Choy is an accomplished executive and entrepreneur with over 25 years of cross-functional experience in the healthcare, biotechnology and professional services industries. He is a co-founder of SHY Therapeutics and provides financial and advisory services to early stage, start-up ventures. Mr. Choy’s areas of expertise include financial and strategic planning, operations, business development, and regulatory and government affairs.

Earlier in his career, Mr. Choy served as the Vice President, Finance and Administration at Kolltan Pharmaceuticals, a Yale affiliated spin-out. Prior to joining Kolltan, Mr. Choy was the Chief Financial Officer for a leading New York/Boston based law firm. During his tenure at Pfizer, Mr. Choy held several senior finance positions including finance director of business planning for the Consumer Health Care Division, finance director of the Asia & Latin America Region for the Animal Health Care Division, and finance director of the U.S. and Asia Region for the Corporate Finance and Treasurer’s Division. He was also instrumental in the integration of the Warner Lambert and Pharmacia acquisitions. Mr. Choy started his career with Arthur Andersen and Company.

Mr. Choy serves as a director and co-chair of BioCT, the bioscience industry association for the state of Connecticut.

Mr. Choy is a CPA and has an MBA in finance from Syracuse University and holds an accounting degree. He is certified in New York State and a member of the American Institute of CPAs.